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ABSTRACT
Prostaglandin E1 (PGE1), known pharmaceutically as alprostadil, has vasodilatory
properties and is used widely in various clinical settings. In addition to acute va-
sodilatoryproperties,PGE1 mayexertbeneﬁcialeVectsbyalteringproteinexpression
of vascular cells. PGE1 is reported to be a potent stimulator of angiogenesis via
upregulation of VEGF expression, which is under the control of the transcription
factor hypoxia-inducible factor 1 (HIF-1). However, the molecular mechanisms
behind the phenomenon are largely unknown. In the present study, we investigated
the mechanism by which PGE1 induces HIF-1 activation and VEGF gene expression
in human aortic smooth muscle cells (HASMCs) and human umbilical vein en-
dothelial cells (HUVECs), both vascular-derived cells. HUVECs and HASMCs were
treated with PGE1 at clinically relevant concentrations under 20% O2 conditions
and HIF-1 protein expression was investigated. Expression of HIF-1 protein and
the HIF-1-downstream genes were low under 20% O2 conditions and increased in
response to PGE1 treatment in both HUVECs and HASMCs in a dose- and time-
dependent manner under 20% O2 conditions as comparable to exposure to 1% O2
conditions.StudiesusingEP-receptor-speciﬁcagonistsandantagonistsrevealedthat
EP1 and EP3 are critical to PGE1-induced HIF-1 activation. In vitro vascular perme-
ability assays using HUVECs indicated that PGE1 increased vascular permeability
in HUVECs. Thus, we demonstrate that PGE1 induces HIF-1 protein expression
and HIF-1 activation under non-hypoxic conditions and also provide evidence that
the activity of multiple signal transduction pathways downstream of EP1 and EP3
receptorsisrequiredforHIF-1activation.
Subjects Cell Biology, Molecular Biology, Anaesthesiology and Pain Management, Pharmacology
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Hypoxia-inducible factor 1 (HIF-1) is a transcription factor originally identiﬁed as a
moleculeresponsibleforhypoxia-inducedexpressionoferythropoietin(Wangetal.,1995).
More recently, the delineation of molecular mechanisms of angiogenesis has revealed a
critical role for HIF-1 in the regulation of angiogenic growth factors. HIF-1 is identiﬁed
as a critical factor in developmental, adaptive and pathological angiogenesis (Hirota &
Semenza,2006).
HIF-1isaheterodimericDNA-bindingcomplexcomposedoftwobasichelix-loop-helix
proteinsofthePER-ARNT-SIM(PAS)family:HIF-1 andHIF-1 (Wangetal.,1995).The
regulation of HIF-1 activity occurs at multiple levels in vivo. Hypoxia induces changes in
the hydroxylation status of well-conserved prolyl and asparaginyl residues of HIF-1,
resulting in protein stabilization and transcriptional activation of HIF-1 (Hirota &
Semenza, 2005; Schoﬁeld & RatcliVe, 2005). Physiological stimuli other than hypoxia can
alsoinduceHIF-1activationandtranscriptionofhypoxia-induciblegenes(Dery,Michaud
& Richard, 2005; Nizet & Johnson, 2009; Pouyssegur & Mechta-Grigoriou, 2006). Signaling
via receptor tyrosine kinases can induce HIF-1 expression by a mechanism independent
of the presence of hypoxia. HER2/neu and IGF-1 receptor activation increases the rate of
HIF-1 proteinsynthesis(Fukudaetal.,2002;Laughneretal.,2001).
Prostaglandins are a member of a group of lipid compounds that are derived
enzymaticallyfromfattyacidsandhaveimportantfunctionsintheanimalbody(Coleman,
Smith & Narumiya, 1994). They are mediators and have a variety of strong physiological
eVectssuchasregulatingthetoneofsmoothmuscletissue.
Among prostanoids, the E type prostaglandins, particularly PGE2 derived from
arachidonic acid, are most widely produced in the body (Coleman, Smith & Narumiya,
1994). Molecular identiﬁcation of the E type prostaglandins receptors was achieved by
theircDNAcloning(Narumiya,Sugimoto&Ushikubi,1999;Sugimoto&Narumiya,2007),
whichrevealedthatthereceptorsareG-protein-coupledreceptors(GPCRs).
Prostaglandin E1 (PGE1), known pharmaceutically as alprostadil, has vasodilatory
properties. In addition to acute vasodilatory properties, PGE1 may exert additional eVects
by altering protein expression of endothelial cell and other types of cells. For example,
PGE1 is reported to be eVective for treating patients with severe hepatitis and primary
graft non-function after liver transplantation (Andrade Jr, Andrade & Santos, 2009).
Moreover, it is reported that PGE1 is a potent stimulator of angiogenesis via upregulation
of VEGF expression (Haider et al., 2005; Inoue et al., 2013; Mehrabi et al., 2003). However,
the molecular mechanisms behind the phenomena are as yet largely unknown. Earlier
studies (Fukuda, Kelly & Semenza, 2003; Han, Michalopoulos & Wu, 2006; Ji et al.,
2010) revealed the mechanism by which PGE2 exposure induces vascular endothelial
growth factor (VEGF) gene expression in HCT116 human colon carcinoma cells, EP1
receptor-overexpressed HE293 cells and Hep2G cells. PGE2 induces the expression of
HIF-1 protein and EP1 receptor activation appears to be necessary and suYcient to
induce HIF-1 expression in HCT116 cells adopting rather higher concentration of the
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 2/20EP1 agonist 17-pt-PGE2 and the antagonist 50 M SC-51322 and 1 M sulprostone. In
contrast, it is reported that PGE1 causes an upregulation of eNOS and VEGF protein
and mRNA expression and decreases HIF-1 in human umbilical vein endothelial cells
(HUVECs) without demonstration of molecular mechanism behind the observation
(Haider et al., 2005). Moreover, there is a report describing that alprostadil suppresses
angiogenesis (Cattaneo et al., 2003). Thus, involvement of the type E prostaglandin
especially PGE1 in VEGF secretion and the subsequent angiogenesis and the molecular
mechanisms behind the phonemenon is largely unknown. The evidence prompted us to
investigate the eVect of PGE1 on HIF-1 activation, VEGF secretion and the initial steps of
angiogenesisadoptingsmoothmusclecellsandendothelialcells.
In the present study, we investigated the mechanism by which PGE1 induces VEGF
gene expression in human aortic smooth muscle cells (HASMCs) and HUVECs and
demonstrated that PGE1 induces HIF-1 activation by the increasing expression of HIF-1
protein and its downstream genes including VEGF in an EP1 and EP3 prostaglandin
receptors-dependent manner. In addition, we aimed to elucidate the consequence of
PGE1-induced HIF-1 dependent VEGF secretion on the initial step of angiogenesis using
humanendothelialcells.
MATERIALS AND METHODS
Cell culture and reagents
Human aortic smooth muscle cells (HASMCs) and human umbilical vein endothelial
cells (HUVECs) were purchased from Kurabo (Osaka, Japan) (Oda et al., 2009). Human
neuroblastoma cell line SH-SY5Y cells obtained from ATCC (Manassas, VA), were
maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS) (Daijo et
al., 2011; Takabuchi et al., 2004). HEK293 cells were maintained in Dulbecco’s Modiﬁed
Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) (Hirota et al., 2004).
PGE1 wasobtainedfromSigma-Aldrich(St.Louis,MO).Lipo-PGE1 wasfromMitsubishi
Tanabe Pharma (Osaka, Japan). PGE1-Alfadex (7f-(1 R, 2 R , 3R )-3-Hydroxy-2[-(1 E, 3
S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentylg heptanoic acid--Cyclodextrin) was from
Ono Pharmaceutical Co. (Osaka, Japan). Cycloheximide (CHX), desferrioxamine (DFX),
LY294002, PD98059, and GF109203X were obtained from Calbiochem (San Diego, CA).
YC-1wasobtainedfromCaymanChemicalCompany(AnnArbor,MI).
Anti-HIF-1 antibody was purchased from BD Biosciences (San Jose, CA) and anti-
HIF-1 antibody was purchased from Novus Biologicals (Littleton, CO). Anti--actin
antibodywaspurchasedfromSigma-Aldrich.
EP receptor-speciﬁc agonists and antagonists
The speciﬁc agonists, ONO-DI-004 for EP1, ONO-AE1-259-01 for EP2, ONO-AE-248
for EP3, ONO-AE1-329 for EP4 and the speciﬁc antagonists, ONO-8713 for EP1,
ONO-AE3-240 for EP3, and ONO-AE2-227 for EP4 were kindly provided by Ono
PharmaceuticalCo.(Suzawaetal.,2000).
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Cells were maintained in a multi-gas incubator (APMW-36, Astec, Japan) and exposed
to hypoxia (1% O2, 5% CO2, and 94% N2 or 5% O2, 5% CO2, and 90% N2) at 37C
(Tanakaetal.,2010;Tanakaetal.,2011).
Immunoblot assays
Whole cell lysates were prepared using ice-cold lysis buVer following a protocol described
previously (Kasuno et al., 2004; Oda et al., 2006; Tanaka et al., 2010). Aliquots of the cell
lysates were fractionated by 7.5% SDS-PAGE and subjected to immunoblot assay using
mouse monoclonal antibody against HIF-1 (BD Biosciences, San Jose, CA) or HIF-1
(H1b234;NovusBiologicals,Littleton,CO)at1:1000dilutionandHRP-conjugatedmouse
monoclonal antibodies against mouse IgG (Amersham Bioscience, Piscataway, NJ, 1:1000
dilution). Anti--actin antibody (Sigma, St. Louis, MO) was used at 1:5000 dilution.
Chemiluminescent signals were developed using ECL reagent (Amersham Biosciences).
TheintensityofeachbandwasquantiﬁedusingImageJsoftware(Odaetal.,2006).
Metabolic labeling assay
The metabolic-labeling protocol is described elsewhere (Kasuno et al., 2004). Brieﬂy,
HASMCswereplatedina10-cmdishand24hlaterwereserum-starvedforafurther12h.
Thecellswerepretreatedwith10MPGE1 or100MDFXfor30mininmethionine-free
Dulbecco’s modiﬁed Eagle’s medium. [35S] Met-Cys was added to a ﬁnal concentration
of 0.3 mCi/ml, and the cells were pulse-labeled for 45 min and then harvested. Whole
cell extracts were prepared and 1 mg of extract was precleared with 60 l of protein
A-Sepharose for 1 h. Anti-HIF-1 antibody (20 l) was added to the supernatant and
the mixture was rotated overnight at 4C. Protein A-Sepharose (40 l) was added
and the mixture rotated for 2 h at 4C, pelleted, and washed ﬁve times with 1 ml of
radioimmune precipitation buVer. The samples were analyzed by SDS-polyacrylamide
gelelectrophoresis.ThegelwasdriedandexposedtoX-rayﬁlm.
Quantitative real-time reverse transcriptase (RT)-PCR analysis
(qRT-PCR)
RNA was puriﬁed using RNeasyTM (Qiagen, Valencia, CA) and treated with DNase.
First-strand synthesis and real-time PCR were performed using the QuantiTect SYBR
Green PCR Kit (Qiagen) following the manufacturer’s protocol. Ampliﬁcation and
detection were performed using the Applied Biosystems 7300 Real-time PCR System
(Applied Biosystems, Foster City, CA) (Oda et al., 2008). PCR primers were purchased
fromQiagen(Odaetal.,2009;Tanakaetal.,2010).Thechangeinexpressionofeachtarget
mRNArelativeto18SrRNAwascalculated.
VEGF ELISA
Secreted VEGF protein levels in culture supernatant were determined with an ELISA kit
(Quantikine Human VEGF ELISA kit; R & D Systems) according to the manufacturer’s
instruction. Values of optical density were measured spectrophotometrically (Microplate
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 4/20Reader 680 XR; Bio-Rad) at 450 nm (correction wavelength set at 570 nm). The standard
curve was made with PrismTM software. In each experiment, all samples and standards
were measured in duplicate. The amount of VEGF released in the supernatant was
expressedinpg/ml(Tanakaetal.,2011).
In vitro vascular permeability assay
The assay kit was purchased from Milliore (Billerica, MA). HUVEC cells were seeded at
200,000 cells per insert and cultured for 72 h. HUVEC monolayer permeability was tested
after a 24 h starvation period. Test inserts were then treated for 18 h with 1 M PGE1 in
basal medium. Monolayers were also treated with basal medium and growth medium
only.Insertswerealsotestedwithoutthecellmonolayer.Theﬂuorescenceoftheplatewell
solutionwasdeterminedusingastandardﬂuorescentplatereader.
Transepithelial electrical resistance measurements
MeasurementoftransepithelialelectricalresistanceinHUVECmonolayerwasperforming
using a Millicell electric resistance system (ERS) ohmmeter (Millipore Corporation,
Bedford, MA) as a barrier function assay (Kimura et al., 2008). This device can measure
electricresistanceofepithelialcellsincultureusingaseparatepairofAg-AgClelectrolodes
and a resistance meter. Fluid resistance was subtracted and net resistance was calculated
as ohm-square centimeter. Results are presented as the mean  S.D. of three independent
wells.
Statistical analysis
DataarepresentedasmeansS.D.Datawereanalyzedusingone-wayanalysisofvariance
followed by Dunnett’s multiple comparison test using Prism version 4c. P < 0:05 was
consideredstatisticallysigniﬁcant(Tanakaetal.,2010;Tanakaetal.,2011).
RESULTS
PGE1 induces HIF-1 protein accumulation in vascular-derived
cells
WiththeaimofevaluatingtheeVectofPGE1 (alprostadil)onHIF-1activity,HASMCsand
HUVECs were treated with or without 1 or 10 M PGE1 under 20% O2 conditions for 4 h
and HIF-1 protein expression was investigated (Figs. 1A–1D). HIF-1 protein expression
was low under 20% O2 conditions (lane 1) and increased in response to PGE1 treatment
inbothHASMCsandHUVECs(lanes2and3)aswellasunder1%O2 conditions(lane4)
(Figs. 1A and 1C). HIF-1 protein expression was not aVected by PGE1 treatment in
either HASMCs or HUVECs. -actin expression remained constant during treatment.
Densitometric analysis showed that both 1 M and 10 M PGE1 statistically signiﬁcantly
induced HIF-1 protein expression as early as 4 h (Figs. 1B and 1D). With the aim of
constructing a time course of the eVect of PGE1 on HIF-1 protein accumulation, cells
were exposed to 1 M PGE1 for 2, 4, and 8 h. The time-course study demonstrated
that 1 M PGE1 induced HIF-1 protein expression as early as 1 h with peak activity
at 4 h (lanes 4) in both HASMCs (Fig. 1E) and HUVECs (Fig. 1F). No toxic eVect was
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 5/20Figure1 PGE1 inducesHIF-1 proteinaccumulationinvascular-derivedcells. Human aortic smooth
muscle cells (HASMCs) (A and B), human umbilical vein endothelial cells (HUVECs) (C and D), and
HEK293 cells (G) were exposed to 1 or 10 M PGE1 under 20% O2 or 1% O2 conditions for 4 h. After
treatment, cells were harvested and whole-cell lysates were subjected to immunoblot assay for HIF-1,
HIF-1, and -actin protein expression. Experiments were repeated thrice (A, C and G). Representative
immunoblots are shown (A and C). (continued on next page...)
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Band intensities were analyzed densitometrically (B and D). Fold induction relative to lane 1 was plotted
as mean  S.D. P < 0:05 compared with the control. HASMCs (E) and HUVECs (F) were exposed to
1 M PGE1 for the indicated times under 20% O2 and were harvested for immunoblot assay for HIF-1
protein. Experiments were repeated twice. Representative immunoblots are shown. (H) HASMCs and
HUVECs were exposed to 10 M PGE1 for 4 h under 20% O2 and were harvested for immunoblot
assay for HIF-2 protein. Experiments were repeated twice. Representative immunoblots are shown.
I. HASMCs were exposed to 1 M PGE1, lipo-PGE1 and PGE1-alfadex under 20% O2 conditions for
4 h. After treatment, cells were harvested and whole-cell lysates were subjected to immunoblot assay for
HIF-1.
detected as judged from an MTT assay (data not shown). PGE1 did not induce HIF-1
protein accumulation in HEK293 cells (Fig. 1G). In contrast, 1 M PGE1 did not aVect
HIF-2 protein expression under 20% O2 conditions in either HASMCs or HUVECs at
4 h (Fig. 1H). There are several preparations of PGE1 available in clinical settings. We
tested the two PGE1 analogues; lipo-PGE1 and PGE1-Alfadex (Fig. 1I). Both lipo-PGE1
and PGE1-Alfadex induced HIF-1 protein accumulation in HASMCs under normoxic
conditions.
PGE1 induces HIF-1 activation and expression of its downstream
genes
We next investigated the eVect of PGE1 on HIF-1-mediated gene expression. The mRNA
expression of genes was assayed by qRT-PCR. PGE1 treatment induced VEGF and GLUT1
mRNA expression in a PGE1-dose dependent manner under 20% O2 conditions in both
HASMCs (Fig. 2A) or HUVECs (Fig. 2B) at 4 h. The fold induction of VEGF mRNA
by PGE1 was less than that of hypoxic exposure (1% O2 conditions). In contrast, the
inductionofGLUT1mRNAwascomparabletothatofhypoxicexposure.Thisisconsistent
with the results of HIF-1 protein expression (Figs. 1A and 1C). The expression of either
HIF-1 or HIF-1 mRNA was not aVected by PGE1. Moreover, PGE1 induced VEGF
protein secretion in both HASMCs (Fig. 3A) or HUVECs (Fig. 3B). The induction of
VEGF mRNA in HASMCs was inhibited by the inhibitor of HIF-1 activation YC-1 or
downregulation of HIF-1 expression by siRNA, indicating that the eVect of PGE1 is
dependent on HIF-1 activation (Fig. 3C). Glut1 mRNA expression was also aVected by
YC-1 and downregulation of HIF-1 expression by siRNA similarly to VEGF mRNA
(Fig.3D).
Differential involvement of EP receptors in PGE1-induced HIF-1
activation
Four types of EP receptors have been identiﬁed for PGE1 (Sugimoto & Narumiya, 2007).
We sought to identify those responsible for PGE1-induced HIF-1 activation. Expression
of EP receptors in HUVECs and HSMACs was examined by qRT-PCR. It is reported that
SH-SY5Y cells express EP1, EP2, EP3, and EP4 receptors (Ji et al., 2010). As shown in
Fig.4A,HASMCsexpressalltypesofEPreceptor.HUVECsexpresstheEP1,EP3,andEP4
receptors.TheEP2receptorwasnotdetectedinHUVECs.
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 7/20Figure 2 PGE1 induces HIF-1 activation and expression of its downstream genes. Human aortic
smooth muscle cells (HASMCs) (A) and human umbilical vein endothelial cells (HUVECs) (B) were
exposed to 1 M or 10 M PGE1 for 4 h under 20% or 1% O2 and harvested for semi-quantitative
RT-PCR for vascular endothelial growth factor (VEGF), glucose transporter 1 (GLUT1), HIF-1 and
HIF-1. Experiments were repeated at least three times in triplicate. Fold induction relative to that
under 20% O2 without PGE1 treatment was plotted. P < 0:05 compared with the control (20% and
no treatment).
Among EP receptor-subtype-speciﬁc ligands, the EP1-speciﬁc ligand ONO-DI-004
(Fig. 4B, lanes 2) and the EP3-speciﬁc ligand ONO-AE-248 (Fig. 4B; lanes 4) induced
HIF-1 protein accumulation in both HASMCs and HUVECs. In contrast, neither
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 8/20Figure3 PGE1 inducesVEGFsecreationinanHIF-1-dependentmanner.HUVECs(A)andHASMCs
(B) were exposed to 1 M PGE1 for 4 h and supernatants of the culture media were subjected to ELISA
for VEGF protein. The concentrations were indicated in pg/ml. P < 0:05 compared with the control
(20% and no treatment). HASMCs were exposed to 1 M PGE1 with 10 M YC-1 for 4 h under 20%
or 1% O2 and harvested for semi-quantitative RT-PCR for VEGF (C) and GLUT1 (D). Fold induction
relativetothatunder20%O2 withoutPGE1 treatmentwasplotted. P <0:05comparedwiththecontrol
(20% and no treatment), #P < 0:05 for comparisons between the indicated groups.
the EP2-speciﬁc ligand ONO-AE1-259-01 (Fig. 4B; lanes 3) nor the EP4-speciﬁc
ligand ONO-AE1-329 (Fig. 4B; lanes 5) induced HIF-1 protein expression at 1 M
concentration.Consistentwiththeseobservations,theEP1-speciﬁcantagonistONO-8713
or the EP3-speciﬁc antagonist ONO-AE3-240 inhibited PGE1-induced HIF-1 protein
accumulation in both HASMCs and HUVECs (Fig. 4C). HIF-1 expression was not
aVected by any agonists of the EP receptors (Fig. 4B). Moreover, qRT-PCR analysis
showed that ONO-DI-004 and ONO-AE-248 induced expression of VEGF mRNA in
both HASMCs (Fig. 5A) and HUVECs (Fig. 5B) at 4 h. qRT-PCR analysis showed
that ONO-8713 and ONO-AE3-240 did suppress but the EP4-speciﬁc antagonist
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 9/20Figure 4 DiVerential involvement of EP receptors in PGE1-induced HIF-1 protein accumulation. (A) Expression of EP1, EP2, EP3, and EP4
receptors in human aortic smooth muscle cells (HASMCs), human umbilical vein endothelial cells (HUVECs), and cells of the neuroblastoma
cell line SH-SY5Y. HASMCs, HUVECs, and SH-SY5Y cells were cultured under 20% O2 and harvested for semi-quantitative RT-PCR for EP1-4
receptors. Experiments were repeated at least three times in triplicate. Fold induction relative to expression in SH-SY5Y cells was plotted as
mean  S.D. HASMCs and HUVECs were exposed to 1 M of EP-receptor-speciﬁc agonists (ONO-DI-004 for EP1, ONO-AE1-259-01 for EP2,
ONO-AE-248 for EP3, and ONO-AE1-329 for EP4) for 4 h (B). HASMCs and HUVECs were exposed to 1 M PGE1 with or without 1 M
EP-receptor-speciﬁc antagonists (ONO-8713 against EP1, ONO-AE3-240 against EP3, and ONO-AE2-227 against EP4) for 4 h (C). The cells were
harvested and the whole-cell lysates were subjected to immunoblot assay for HIF-1 and -actin protein expression. Experiments were repeated
twice. Representative immunoblots are shown.
ONO-AE2-227 did not suppress VEGF or GLUT1 mRNA induction by PGE1 expression
statisticallysigniﬁcantlyinbothHASMCs(Fig.5C)orHUVECs(Fig.5D).
Effect of PGE1 on stability and synthesis of HIF-1
The balance between synthesis and degradation determines HIF-1 protein levels. With
the aim of exploring the mechanism for HIF-1 protein induction by PGE1, HIF-1
protein half-life in the cells was examined. HASMCs and HUVECs were treated with
PGE1 or DFX for 4 h to induce HIF-1 protein accumulation. Then, CHX was added to
block ongoing protein synthesis. In the presence of CHX, HIF-1 protein expression was
not detected at 30 min in PGE1-treated cells but persisted in DFX-treated cells in both
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 10/20Figure 5 DiVerential involvement of EP receptors in PGE1-induced HIF-1 activation. HASMCs and
HUVECs were exposed to 1 M of EP-receptor-speciﬁc agonists for 4 h and harvested for semi-
quantitative RT-PCR for VEGF (A) and GLUT1 (B). Fold induction relative to that under 20% O2
without PGE1 treatment was plotted. P < 0:05 compared with the control (no treatment). HASMCs
and HUVECs were exposed to 1 M of EP-receptor-speciﬁc antagonists with 10 M PGE1 for 4 h and
harvested for semi-quantitative RT-PCR for VEGF (C) and GLUT1(D). Fold induction relative to that
under20%O2 withoutPGE1 treatmentwasplotted. P <0:05comparedwiththecontrol(noantagonist
with PGE1).
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 11/20HASMCsandHUVECs(Fig.6A).TheseresultsstronglysuggestedthatHIF-1 expression
inPGE1-treatedcellsisdependentmainlyuponongoingproteinsynthesis.
With the aim of determining the rate of HIF-1 synthesis, serum-starved HUVECs
were pretreated with PGE1 or DFX for 30 min and then pulse-labeled with [35S] Met-Cys
for 40 min, followed by immunoprecipitation of HIF-1 (Fig. 6B). In contrast to control
serum-starved cells, 35S-labeled HIF-1 clearly increased in PGE1-treated cells (lane 2),
whereas the amount of labeled HIF-1 protein did not increase in cells treated with
DFX (lane 3), relative to the control. Thus, both CHX addition and metabolic labeling
experiments provide evidence for increased synthesis of HIF-1 in response to PGE1
treatment. Immunoblotting analysis against the same lysates with anti--actin antibody
wasindicatedasloadingcontrolofthelysates(Fig.6B).
To examine the signaling pathways leading to HIF-1 protein induction in HUVECs
and HASMCs, we focused on various kinases, including PI3K, mitogen-activated protein
kinase (MAPK), protein kinase C (PKC) and mammalian target of rapamycin (mTOR)
(Fukuda,Kelly&Semenza,2003).
HIF-1 activity induced by the stimulation of receptor tyrosine kinases or G protein-
coupled receptors has been reported to require MAPK and PI3K signaling (Fukuda, Kelly
& Semenza, 2003; Hirota et al., 2004). Cells were pretreated with LY294002, PD98059
or GF109203X, which are selective inhibitors of PI3K, MAPK and PKC, respectively, for
30 min, and then treated with 10 M PGE1 for 4 h and harvested for immunoblot assay
in both HASMCs and HUVECs (Fig. 6C). All the inhibitors inhibited the induction
of HIF-1 protein expression by PGE1. HIF-1 protein expression was not induced
nor aVected by any of the kinase inhibitors. Consistent with kinase inhibitor-mediated
inhibition of HIF-1 protein expression, LY294002, PD98059, or GF109203X also
suppressedPGE1-inducedVEGFandGLUT1mRNAexpression(Fig.6D)inHASMCs.
PGE1 increases permeability of vascular barrier reconstituted with
HUVECs
With the aim of determining whether PGE1 altered vascular barrier function, in vitro
vascular permeability assay using HUVECs were performed (Fig. 5). HUVECs were
seeded, allowed to form a monolayer for 72 h, and treated with or without 1 M PGE1,
theEP1-speciﬁcligandONO-DI-004ortheEP3-speciﬁcligandONO-AE-248forafurther
18 h under 20% O2 conditions and the extent of permeability was then determined as
describedinMaterialsandMethods.AsshowninFig.5A,PGE1 increasedthepermeability
of vascular barrier attained by HUVECs. The EP1 agonist ONO-DI-004 and the EP3
agonist ONO-AE-248 also decreased in transepithelial resistance as well as PGE1. The
increase ofthe permeabilitywas partiallyprevented bytreatment withthe HIF-1 inhibitor
YC-1 or siRNA against HIF-1 (Fig. 7A). In addition, we also examined the permeability
adopting transepithelial electrical resistance measurements. Transepithelial resistance was
decreased24haftertreatmentwithconditionedmediaderivedfromHUVECstreatedwith
1 M PGE1, ONO-DI-004, or ONO-AE-248 treatment and the treatment with YC-1 or
siRNAagainstHIF-1 preventedtheincreaseofthepermeability(Fig.7B).
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 12/20Figure 6 EVect of PGE1 on stability and synthesis of HIF-1. (A) Human aortic smooth muscle cells
(HASMCs) and human umbilical vein endothelial cells (HUVECs) were exposed to 1 M PGE1 or
100 M DFX or incubated for 4 h, and CHX was added to a ﬁnal concentration of 100 M. The cells were
incubated for 0 to 30 min, and whole-cell lysates were subjected to immunoblot assay using anti-HIF-1
or - antibodies. (B) Serum-starved HASMCs were pretreated with no drug and 1 M PGE1 for 30
min in Met-free medium. [35S]Met-Cys was added, and the cells were incubated for 60 min prior to
preparation of cell lysates. Aliquots of 1 mg of the lysates were subjected to immunoprecipitation with
anti-HIF-1 antibody, separated by SDS-PAGE and exposed. Aliquots of 50 g of the same lysate were
separately subjected to immunoblotting analysis (continued on next page...)
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with anti--actin antibody. (C) HASMCs and HUVECs were exposed to vehicle or 1 M PGE1 for 4 h
in the presence of 10 M LY294002 (LY), 50 M PD98059 (PD), or 5 M GF109203X (GF). The cells
were harvested and the whole-cell lysates were subjected to immunoblot assay for HIF-1 and -actin
protein expression. Experiments were repeated at least twice. Representative immunoblots are shown.
(D) HASMCs were exposed to vehicle or 1 M PGE1 for 12 h in the presence of 10 M LY294002 (LY), 50
M PD98059 (PD), or 5 M GF109203X (GF). Cells were harvested and subjected to semi-quantitative
RT-PCR for VEGF and GLUT1. Experiments were repeated three times. Fold induction relative to that
under 20% O2 without PGE1 treatment was plotted. P < 0:05 compared with the control (20%, PGE1
treatment without any kinase inhibitors).
Figure7 PGE1 increasespermeabilityofvascularbarrierreconstitutedwithHUVECs. HUVECs were
seeded, allowed to form a monolayer for 72 h. (A) Cells were treated with 10 M PGE1 for a further
18 h, after which the extent of permeability was determined as described in Materials and Methods.
Fold induction relative to the control (cells without PGE1 treatment) was plotted as mean  S.D.
(n D 4). P < 0:05 compared with the control. (B) Cells were treated for a further 18 h under 20% O2
conditions with conditioned media derived from HUVECs treated with 1 M PGE1 with or without the
treatment with YC-1or siRNA against HIF-1, ONO-DI-004, or ONO-AE-248 treatment for 24 h. Then,
transepithelial electrical resistance was measured. Percent suppression of resistance relative to the control
(cells without PGE1 treatment) was plotted as mean  S.D. (n D 4). p < 0:05 vs. control. RER, relative
electrical resistance.
DISCUSSION
In this study, we demonstrated that the prostanoid PGE1 induced HIF-1 activation by
increasing HIF-1 protein expression in an EP1- and EP3-receptor-dependent manner in
thevascularderivedcellsHUVECsandHASMCs.Inaddition,wealsoindicatedthatPGE1
facilitatedtheinitialstepofangiogensis,stimulationandreorganizationofbasallaminaof
endothelialcells.
Because eVective-site concentrations of PGE1 in clinical settings are estimated to range
from 100 to 5 M, the concentration of PGE1 in the present study is close to clinically
relevant levels (Cawello et al., 1995; Weiss et al., 2004). In this study, we used three types of
PGE1; PGE1 and PGE1 conjugated to lipid microsphere and cyclodextrin, both of which
arewidelyusedinclinicalﬁeld.
It is well known that the intracellular protein stability of both HIF-1 and HIF-2
is regulated by essentially the same HIF--prolyl hydroxylase-dependent mechanism
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 14/20(Hirota & Semenza, 2005; Schoﬁeld & RatcliVe, 2005). PGE1 treatment did not induce
the expression of the HIF-2 protein (Fig. 1D). The experimental results presented as
Fig. 6A show that PGE1 treatment does not prolong the intracellular half-life of HIF-1
protein as long as prolyl hydroxylase DFX does. Together, the evidence suggests that PGE1
does not aVect the protein stability of HIF-1 at least in either HUVECs or HASMCs.
The other known mechanism of induction of HIF-1 protein expression is regulation of
HIF-1 translation from mRNA (Dery, Michaud & Richard, 2005; Fukuda et al., 2002;
Fukuda, Kelly & Semenza, 2003; Laughner et al., 2001). The neosynthesis of HIF-1,
especially induced by certain types of nitric oxide donors, growth factors, and agonists
of GPCRs including acetylcholine, thrombin, and PGE2, is dependent on the activity of
PI3K, AKT and mTOR (Fukuda et al., 2002; Fukuda, Kelly & Semenza, 2003; Gorlach et al.,
2001; Hirota et al., 2004; Kasuno et al., 2004). Notably, it is reported that PGE2 induced
HIF-1 protein expression by increasing HIF-1 protein translation from the mRNA in
an EP1 receptor signal-dependent manner (Fukuda, Kelly & Semenza, 2003). As shown
in Fig. 6C, PGE1-induced HIF-1 expression was inhibited by treatment with LY294002,
PD98059, or GF109203X. Moreover, Fig. 6B indicates that PGE1 induces the neosynthesis
of HIF-1 protein. In addition, PGE1 increased the expression level of HIF-1 mRNA
but not that of HIF-1 mRNA in both HUVECs and HASMCs (Figs. 2A and 2B). Taking
theseobservationstogetherwithourexperimentalﬁndingsthatPGE1 doesnotprolongthe
half-life of HIF-1 protein (Fig. 6A) and that PGE1 enhances the neosynthesis of HIF-1
protein (Fig. 6B), we conclude that PGE1 activates HIF-1 mainly by increasing HIF-1
proteinexpressionbyenhancementoftranslationofHIF-1 invascular-derivedcells.
We showed that HASMCs express mRNA of all of the EP receptors at levels comparable
to those of neuronal SH-SY5Y cells, which express all the EP receptors functionally
(Ji et al., 2010) (Fig. 4A). We also demonstrated that HUVECs express mRNA of EP1,
EP3, and EP4 prostanoid receptors (Fig. 4A). This result is consistent with previous
ﬁndings (Amano et al., 2003; Kaneshiro et al., 2009). In both HASMCs and HUVECs,
theEP1-orEP3-receptor-speciﬁcagonistsONO-DI-004orONO-AE-248inducedHIF-1
protein accumulation (Fig. 4B; lanes 2 and 4) and the HIF-1-downstream gene VEGF
expression (Fig. 5A and 5B) and Glut1 expression (Figs. 5C and 5D) in both HASMCs
andHUVECs.Incontrast,theEP2-andEP4-receptor-speciﬁcagonistsONO-AE1-259-01
and ONO-AE1-329 failed to induce HIF-1 protein accumulation (Fig. 4B; lanes 3 and 5)
and HIF-1 activation (Figs. 5A–5D). Ki value of PGE1 for the other prostanoid receptor
IP receptor is reported to be 33 nM, which is equivalent to that of EP1 receptor 36 nM
(Narumiya, Sugimoto & Ushikubi, 1999). The evidence suggests that IP receptors may
contributeatleastpartiallytotheactivationofHIF-1inHASMCsandHUVECs.However,
we also demonstrated that the EP1- and EP3-receptor-speciﬁc antagonists ONO-8713 or
ONO-AE3-240 signiﬁcantly suppressed PGE1-induced HIF-1 expression (Fig. 4C, lanes
2 and 3) and induced VEGF mRNA expression (Fig. 5C). The evidence clearly shows that
PGE1 induces HIF-1 activation in an EP1- and EP3-receptor-dependent manner at least
in HASMCs and HUVECs. The results are consistent with the precedent studies (Fukuda,
Kelly & Semenza, 2003; Ji et al., 2010), in which the critical role of the EP1 receptor in
Suzuki et al. (2013), PeerJ, DOI 10.7717/peerj.220 15/20PGE2-induced HIF-1 activation was emphasized based on the evidence with an EP1
receptor antagonist in established cell lines. In addition to the EP1 receptor, we found
that the EP3 receptor played a signiﬁcant role in PGE1-induced HIF-1 activation from
primary cultured cells of vascular origin. Signal transduction pathways of EP subtypes
have been studied by examination of agonist- induced changes in second messengers such
as cAMP, Ca2C, and inositol phosphates and of agonist-induced changes in activities of
downstream kinases (Sugimoto & Narumiya, 2007). As shown in Fig. 6C, PGE1-induced
HIF-1 activation is dependent on PI3K, MAPK, PKC, and mTOR in agreement with the
observations that kinase inhibitors suppress the activation of HIF-1 protein expression
and HIF-1 activation. This is also consistent with the precedent studies (Fukuda, Kelly &
Semenza, 2003; Ji et al., 2010), suggesting that PGE1 utilizes the common mechanism of
enhancementofHIF-1 translation.
Figures 7A and 7B illustrate that PGE1 increased the permeability of the vascular sheet
reconstituted on collagen-coated inserts by HUVECs. The PGE1-HIF-1-VEGF axis may
havecontributedtothisincreasedvascularpermeabilitywithinaclinicallyrelevantdose.
In a precedent study, it is reported that PGE1 induced VEGF and eNOS expression in
an HIF-1-independent manner (Haider et al., 2005). It appears that there is a discrepancy
between that report and our data but the reasons for the discrepancy are not currently
clear. First, Haider et al. did investigate the expression of HIF-1 mRNA by conventional
RT-PCR. We assayed the expression of HIF-1 mRNA by qRT-PCR but the change of
the expression of HIF-1 mRNA was marginal (Figs. 2A and 2B). Second, it should be
pointed out the basal expression of HIF-1 protein under normoxia was rather higher in
their study compared to ours. Third, we conﬁrmed the involvement of HIF-1 activation
by inhibiting study adopting YC-1 and knocking down by siRNA againt HIF-1 (Figs. 3C
and7).
CONCLUSIONS
We demonstrate that PGE1 induces HIF-1 protein expression and HIF-1 activation in a
clinicallyrelevantdoseandformulationofdrugandalsoprovidesevidencethattheactivity
ofmultiplesignaltransductionpathwaysdownstreamofEP1andEP3receptorsisrequired
for HIF-1 activation by PGE1. Moreover, we indicate that PGE1 treatment induces the
initialstepofangiogenesisinHUVECsinanHIF-1-dependentmanner.
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